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ABSTRACT
Inhaled corticosteroids are potent and effective treat-
ment agents for controlling symptoms of childhood
asthma. However, there are no predictive factors that
help to determine which patients with asthma are likely
to be tapered off inhaled corticosteroids successfully.
We examined whether any factor or combination of
factors could help the clinician safely discontinue
inhaled steroid therapy. Thirty-six asthmatic children
whose symptoms were stable on low-dose beclo-
methasone dipropionate (BDP) were divided by
parental choice into two groups: maintenance BDP 
(n = 11) and no BDP (n = 25). Methacholine inhal-
ation tests were performed at the beginning of the
study and after 1 month. Twelve children (48%) who
had BDP discontinued developed exacerbations after
2–3 months, whereas there were no problems in the
maintenance group. The no BDP group was retrospec-
tively divided into two subgroups: exacerbation (+)
and (–). The threshold to methacholine in the exacer-
bation (+) subgroup decreased significantly in
advance of clinical symptoms. The two subgroups
were analyzed statistically by two-group discriminant
function analysis. The change in threshold to metha-
choline, the dose and potency of drugs, duration of
asthma and gender (female) correlated with exacer-
bation. These results suggest that discontinuation of
inhaled steroids should be done carefully, even in
stable asthmatic children. The methacholine inhal-
ation test, gender, drugs and history may be used as
references for discontinuing inhaled steroids.
Key words: beclomethasone dipropionate, bronchial
asthma, bronchial sensitivity, children.
INTRODUCTION
Bronchial hypersensitivity in asthma can be assessed by
inhalation testing with bronchoconstricting agents, such
as methacholine.1 The degree of response to broncho-
constricting agents correlates well with the severity of the
disease.2,3 Recent studies have suggested that chronic
bronchial inflammation, characterized by preferential
infiltration of eosinophils, is an important factor in the
development of hypersensitivity.4,5 Inhaled corticosteroids
are known to reduce bronchial sensitivity and are now
widely used in asthma therapy.6,7 However, evaluating
long-term use of inhaled corticosteroids, such as beclo-
methasone dipropionate (BDP), is controversial because
of the possibility of adverse events such as growth retar-
dation. Although BDP at 800 m g/day or less is generally
accepted to be clinically safe,8,9 200–800 m g/day may
affect the adrenal function of children.10 Furthermore,
inhaled corticosteroids sometimes induce oropharyngeal
candidiasis, skin atrophy11 and glaucoma.12 Thus, the
clinician should maintain the lowest effective level of
inhaled corticosteroids. It is important to emphasize the
step-down in inhaled steroids during asthma therapy as
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well as step-up in steroids.13 Bronchial sensitivity has been
reported to increase within 1 week to 3 months after ces-
sation or reduction of inhaled corticosteroid therapy.14–18
We have attempted to describe factors to help the clinician
safely discontinue inhaled corticosteroids.
METHODS
Subjects
Thirty-six asthmatic children (24 males and 12 females;
age range, 8–19 years; mean, 12 years) treated at the
out-patient clinic of Department of Allergy, National
Children’s Hospital were enrolled in this study with
patients’ and/or parents’ informed consent about con-
secutive examination. The study was carried out from
May 1996 to December 1996. All children were positive
for IgE antibody for Dermatophagoides farinae (CAP
system; Pharmacia, Uppsala, Sweden). They had been
treated with low-dose inhaled BDP (100–200 m g/day)
and were stable for at least 6 months (ratio of forced 
expiratory volume in 1 second (FEV1.0%) > 70%). Other
clinical features and initial examination data for these
patients are shown in Table 1. Subjects had received no
oral or parenteral corticosteroid therapy during the pre-
ceding year. Parents were instructed to control allergens
in the home environment. Instructions included using
pillows consisting of only small fragmented plastic tubes,
vacuuming floors, carpets and quilts once a week or
more with a powerful (> 300 W) vacuum cleaner and
avoiding stuffed dolls and furry pets.
Study design
This study consisted of two parts. Initially, we examined
the effect of discontinuing BDP. Several laboratory tests,
such as the methacholine inhalation test, were performed
on all patients at the beginning of the study and 1 month
after the cessation of BDP. Then we assessed which
factors contributed to the exacerbation of asthma among
those who discontinued BDP.
We divided subjects who were stable for at least 
6 months into two groups: the maintenance BDP group,
whose parents wished to continue BDP (n = 11), and the
no BDP group, whose parents wished to discontinue BDP
(n = 25). The no BDP group was retrospectively divided
into two subgroups: an exacerbation (+) group, whose
condition worsened after discontinuation, and an exac-
erbation (–) group, whose condition remained stable.
Several laboratory tests, including the methacholine
inhalation test, pulmonary function test and measure-
ment of blood eosinophil count and serum eosinophil
cationic protein (ECP), were performed at the beginning
of the study and 1 month after cessation of BDP. Both
groups were evaluated clinically for 3 months.
We evaluated the following 11 factors for their corre-
lation with worsening asthma: gender, duration of
asthma, duration of remission, present therapeutic score,
past severity, duration of BDP use, initial threshold to
methacholine, change in threshold to methacholine,
FEV1.0%, blood eosinophil count and serum IgE value.
Asthma exacerbation was defined as the use of a
bronchodilator more than three times per day or the use of
another anti-asthma drug for 2 consecutive days or rapid
deterioration of symptoms. Compliance with anti-asthma
drug therapy, asthmatic condition and the subjects’ daily
asthma diaries were evaluated every 2 weeks. The asth-
matic condition was assessed daily and was based on the
asthma diary and asthma symptom score as follows: severe
attack, 9 points; moderate attack, 6 points; minor attack, 
3 points; and occasional wheezing, 1 point. Past asthma
severity was derived from clinical charts based on admission
history (4 for frequent or severe attacks; 3 for occasional or
moderate attacks; 2 for few or mild attacks; 1 for none 
or mild attack). The present therapeutic score before dis-
continuing the inhaled corticosteroids was defined as the
sum total of all anti-asthma drugs used in a period of 
1 month based on the Japanese Society of Pediatric Allergy
and Clinical Immunology guidelines (Table 1).19
Pulmonary function and inhalation 
provocation test
Patients were requested to discontinue all anti-asthma
drugs for at least 12 h before the test. The FEV1.0%, peak
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Table 1 Therapeutic score
Drugs Method Score
Steroid Inhaler 1.0/each puff (50 m g)
b 2-stimulant Internal use 0.5/each time
Inhaler 0.5/each puff
Theophylline Internal use 2.0/each time




Internal use 1.0/each time
Immunotherapy Injection 4.0/each time
Therapeutic score as defined by the Japanese Society of Pediatric
Allergy and Clinical Immunology. The score was calculated as a sum
for all anti-asthma drugs used in 1 month.
expiratory flow (PEF) and forced vital capacity (FVC) were
measured by using an autospirometer (AS-300; MINATO
Ltd, Osaka, Japan). Patients were instructed to measure
their PEF twice daily by using peak flowmeters. The PEF
variability was calculated as follows:
We evaluated mean PEF variability each month as an
indicator of pulmonary function.20 Bronchial sensitivity
was measured using an Astograph (TCK-6100H; Chest
Corp., Tokyo, Japan), a direct-writing recorder of the
dose–response curve for respiratory resistance (Rrs)
during continuous inhalation of methacholine at step-
wise incremental concentrations.21 The test was done in
the following manner: Rrs was measured by the forced
oscillation method. Two-fold increasing concentrations of
methacholine chloride diluted in physiologic saline from
0.049 to 25 mg/dL, were inhaled. The Rrs increased
gradually with increasing methacholine concentrations.
When the Rrs reached twice the initial value or the patient
felt dyspnea, salbutamol was administered. The indicator
of bronchial sensitivity was the cumulative dose of metha-
choline (Dmin) at the inflection point where the Rrs began
to increase.
Eosinophil cationic protein
Serum ECP levels were measured with a monoclonal
antibody-based fluorometric assay (Pharmacia, Uppsala,
Sweden).
Statistical analysis
We used the Mann–Whitney U-test to analyze the clinical
features of the two groups. Logarithmic transformation
was used when analyzing Dmin and IgE values. When the
changes in FEV1.0%, log Dmin and attack scores were
compared between the three groups (maintenance BDP
group, exacerbation (+) subgroup and exacerbation (–)
subgroup), we applied the repeated measure of analysis
of variance with the Greenhouse–Geisser method.
Results were considered significant at a P value < 0.05.
Multiple comparisons with the Dann-modulus procedure
were used for comparisons of initial and subsequent
values between the three groups, as well as data during
the observation period. Factors attributed to the exa-
cerbation of asthma were analyzed using two-group
discriminant function in the no BDP group. The degree of
correlation with asthma exacerbations was evaluated by
partial correlation coefficients (PCC).
RESULTS
Characteristics of the subjects
There were no significant differences in baseline character-
istics, such as duration of no attack, duration of BDP use
and initial threshold of methacholine (shown in Table 2)
between the maintenance BDP group, whose parents
wished to continue BDP (n = 11) and the no BDP group,
whose parents wished to discontinue BDP (n = 25). Twelve
of the 25 subjects (48%) in the no BDP group had an
exacerbation of symptoms after cessation (from 5 to 
12 weeks: mean 8.1 weeks), while there were no exacer-
bations in the maintenance BDP group during the
observation period (P < 0.01).
Changes in laboratory findings
Among the laboratory findings 1 month after cessation of
BDP, only deterioration of the threshold to methacholine
predicted exacerbation in the no BDP group. There were
no significant changes with regard to asthma symptom
scores between the three groups (repeated-measure
ANOVA, P < 0.001). Children in the exacerbation (+) 
subgroup showed increasing asthma symptom scores 
2 months after cessation (multiple comparison with Dann-
modulus 5% significance (Fig. 1) ). As shown in Fig. 2,
there was a significant change in the threshold to metha-
choline in the three groups (repeated-measure ANOVA, 
P < 0.001). The Dmin in the exacerbation (+) subgroup
deteriorated significantly from 2.25 ± 0.89 units to 0.37
± 0.10 units. Expressed logarithmically, it decreased from
– 0.13 ± 0.22 to – 0.69 ± 0.16 1 month after cessation
of BDP (multiple comparison with Dann-modulus, 5% sig-
nificance). There were no significant changes in the
threshold to methacholine in the maintenance BDP group
or in the exacerbation (–) subgroup (from 1.71 ± 1.01
units to 2.64 ± 1.18 units and from 2.50 ± 0.73 units to
3.27 ± 1.08 units, respectively; and expressed logarith-
mically, from – 0.233 ± 0.20 to – 0.01 ± 0.19 and from
0.11 ± 0.16–0.18 ± 0.17, respectively). When values
for the threshold to methacholine were compared between
the three groups, there were no significant differences at
baseline. However, at 1 month after cessation the thresh-
old to methacholine in the exacerbation (+) subgroup was
significantly lower than in the other two groups (multiple
comparison with Dann-modulus 5% significance).
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Daily PEF variability(%) = ((PEF maximum – PEF
minimum)/mean PEF) · 100
There were no significant differences with regard to 
the FEV1.0% between the three groups (repeated-measure
ANOVA, P = 0.82). There were no significant differences in
the mean variability of PEF before and at 1 month after
cessation of BDP (from 5.09 ± 3.07% to 5.69 ± 4.14%,
repeated-measure ANOVA, P = 0.691) in the exacerbation
(+) subgroup. Eosinophil counts and serum ECP levels
did not differ significantly before and at 1 month after ces-
sation of the therapy, even in the exacerbation (+)
subgroup (n = 9, from 528.5 ± 378.1 /mm3–585.4
± 346.8 /mm3 and from 19.7 ± 7.5 µg/mL to 27.2
± 15.2 m g/mL, respectively; repeated-measure ANOVA,
P = 0.67 and P = 0.24, respectively).
Factors correlating with exacerbation
Possible predictive factors were then analyzed by using
the two-group discriminant function. Variables with high
PCC with exacerbations are shown in Table 3: long 
duration of asthma (PCC = –0.5627), deterioration of
threshold to methacholine (PCC = 0.5547), gender
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Table 2 Characteristics of the 36 subjects
Fig. 1 Asthma symptom scores for the no beclomethasone
dipropionate (BDP) groups with (d; n = 12) and without (j;
n = 13) exacerbation and the maintenance BDP group (s;
n = 11). Data are the mean and SEM of the score points.
During the observation period, there was a significant differ-
ence in asthma symptom scores between three groups
(repeated-measurement A N OVA , p < 0.001). After 2 months,
asthma attack score from baseline increased significantly
among the subjects in the discontinued group with exacerba-
tion (*multiple comparison 5% significance).
Fig. 2 The minimum dose of methacholine (log Dmin) were
evaluated as the indicator of bronchial sensitivity. There was
a significant difference in threshold to methacholine among
the three groups (repeated-measurement A N OVA , p < 0.001).
The bronchial sensitivity of the subjects in the discontinued
group with exacerbation (d; n = 12) decreased significantly
from baseline 1 month after cessation of beclomethasone
dipropionate (BDP) (*multiple comparison 5% significance),
whereas there were no significant changes in the on-mainte-
nance group (s; n = 11) and the no exacerbation subgroup
(j; n = 13). The threshold to methacholine at 1 month was
significantly lower in the discontinued group with exacerbation
compared with the other two groups (*multiple comparison 5%
significance).
Maintenance BDP group No BDP group P value
No. patients 11 25
Age (years) 12.3 (3.8) 12.6 (4.2) NS
Gender (Male/Female) 8:3 16:9 NS
Duration of asthma (years) 9.5 (4.1) 9.7 (3.3) NS
Duration of no attack (months) 8.7 (3.1) 13.3 (10.3) NS
Past severity of asthma 1.9 (0.7) 2.0 (0.9) NS
Duration of BDP use (months) 25.7 (15.4) 32.0 (27.0) NS
Therapeutic score 251.4 (79.6) 261.5 (88.9) NS
Serum lgE (U/mL) 1234 (208) 1050 (233) NS
FEV1.0% 82.5 (6.7) 83.6 (5.7) NS
Initial threshold to methacholine (unit) 1.72 (3.38) 2.38 (2.79) NS
Baseline characteristics of 36 subjects. Data are the mean (SD). The two groups were compared using the Mann–Whitney U-test or Fisher’s exact
probability test. Results were considered significant at P < 0.05. BDP, beclomethasone dipropionate; FEV, forced expiratory volume.
(female: PCC = –0.5500) and high therapeutic score
(PCC = –0.5461). Significance (P < 0.05) was defined
when the absolute value of PCC was greater than
0.5140 (probability of error, u = 0.0622, F = 0.0306).
DISCUSSION
Inhaled corticosteroids, such as BDP, are known to reduce
bronchial sensitivity and are widely used for treating
asthma associated with eosinophilic inflammation of the
bronchi.4–6 Early treatment with inhaled corticosteroids
has recently been reported to be effective even in child-
hood asthma.7 However, adverse events associated with
the long-term use of corticosteroids, such as BDP inhalers,
are still controversial.8–11 Recent treatment guidelines
emphasize the importance of regular monitoring to
control asthma with minimum of medication.20 Here, 
we have tried to determine at what point the clinician 
can discontinue BDP therapy in asthmatic children who
have remained stable for at least 6 months (13.3 ± 10.3
months).
In the no BDP group, 48% of patients developed
exacerbations, as opposed to none in the maintenance
BDP group (P < 0.01). These results indicate that airway
hyperresponsiveness did not resolve after 6 months of
remission and support the findings of other reports that
inhaled corticosteroids suppress the underlying mecha-
nism of asthma, but do not cure the disease.17 It has been
reported that bronchial sensitivity returns to pretreatment
levels within 1–2 weeks after a course of 6–8 weeks 
of 400–800 m g budesonide.14,15 However, others have
reported that the sensitivity remains unchanged for at
least 3 months after cessation of a course of 1 year of
400 m g budesonide.16 An increase in sputum production
is one of the first symptoms encountered in asthmatic
patients who worsen after discontinuing inhaled cortico-
steroids, suggesting that inflammation persists even
during asymptomatic periods.16 Therefore, we evaluated
the degree of cough, sputum and occasional wheezing or
stridor in order to assess mild asthmatic symptoms in 
children. We found that the threshold to methacholine
deteriorated before symptoms developed. We believe
that the initial inflammatory changes occur at the
mucosal level and include an increase in output from the
mucous glands, along with microvascular leakage and
edema. This cascade may lead to airway narrowing and
changes may increase bronchial sensitivity.22 Corti-
costeroids have been reported to reduce epithelial
damage, vascular leakage and the recruitment of inflam-
matory cells such as eosinophils.23 Serial measurements
of serum ECP24 and PEF variability25 have been reported
to be useful for evaluating asthma. However, in the
present study, FEV1.0%, PEF variability, eosinophil counts
and serum ECP levels at 4 weeks after the cessation of
BDP were not useful; only a change in the threshold to
methacholine was found to predict an exacerbation.
We examined the characteristics of patients whose
symptoms worsened after discontinuation of BDP and
found correlation with the following factors: deterior-
ation of the threshold to methacholine, high therapeutic
score, long duration of asthma and female gender.
These factors should be considered before inhaled corti-
costeroid therapy is discontinued.
We conclude the therapeutic effect of inhaled steroids
can be maintained for approximately 1 month after 
they are discontinued. Therefore, cautious reduction is
indicated for children in remission. Furthermore, the
methacholine inhalation test and patient’s profile
should be used when clinically stable asthmatic children
or their parents wish to discontinue inhaled corti-
costeroids. Further long-term studies are necessary to
evaluate the influence of seasonal and non-seasonal
allergen exposure,26 viral respiratory infections27 and
sinusitis28 in the management of steroid withdrawal.
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Table 3 Correlation between patient background and
asthma exacerbation
Explanatory variables PCC
Duration of asthma – 0.5627*
Change in threshold to methacholine – 0.5547*
Gender – 0.5500*
Therapeutic score – 0.5461*
Eosinophil count – 0.4303*
Duration of BDP use – 0.4275*
Past asthma severity – 0.4258*
FEV1.0% – 0.4235*
Initial threshold to methacholine – 0.3276•
Serum IgE – 0.1367*
Duration of remission – 0.1210*
F value – 0.0306*
Probability of error – 0.0622*
Two-group discriminant function with regard to the factors impli-
cated in asthma exacerbation.*Results were considered significant at
5% IP.C.C.I > 0.5140. PCC, partial correlation coefficient; BDP,
beclomethasone dipropionate; FEV, forced expiratory volume.
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